Elucid Bioimaging Inc.

About Elucid Bioimaging Inc.

Elucid is an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis through advanced plaque analysis. Their mission is to drive patient-specific therapeutic decisions by offering non-invasive diagnostics that reveal detailed plaque composition to prevent heart attacks and strokes.

Products & Services

PlaqueIQ™:The only FDA-cleared, non-invasive CTA plaque assessment powered by ground-truth histology, providing detailed lesion-level plaque composition data to support tailored treatment and clinical decisions.

Elucid FFRCT:A forthcoming product leveraging histology-based plaque composition to calculate lesion-level FFRCT measurements.

Elucid Clinical Research:CTA analysis capabilities for research on events tracking, pharmaceutical studies, and more.

Specialties

AI Medical Technology Atherosclerosis Analysis Plaque Characterization CT Virtual Histology Non-Invasive Diagnostics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 80000000 MR: - FA: $80 million FAN: 80000000	D: 2023-11-09 FD: 2023-11-09	1 investors

Series C Latest

2023-11-09

$80.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard E. Kuntz

Board Director

S

Shamiram Feinglass

Managing Director at Manatt Health

LinkedIn (Pro only)

R

Renu Virmani

President & Medical Director at CVPath Institute

S

Scott Huennekens

Chairman of the Board

K

Kelly Huang

President & CEO

B

Blake Richards

Chief Operating Officer

View 14 more team members with Pro

Unlock Full Team Directory

Recent News